Compare GSK plc (GSK) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Indonesia Energy Corporation Limited — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Indonesia Energy Corporation Limited trades at $2.77 (market cap $43.24M). The key difference: GSK plc is far larger — about 2124.9× Indonesia Energy Corporation Limited's market cap, and GSK plc pays a 3.9% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Indonesia Energy Corporation Limited for 24 Days on average.
| GSK | INDO | |
|---|---|---|
Market Cap | $91.88B | $43.24M |
Volume | 7,730,529 | 116,953 |
Sector | Health | Energy |
52-Week High | $61.18 | $6.74 |
52-Week Low | $43.24 | $2.49 |
Typical Hold Time | 93 Days | 24 Days |
Enterprise Value | $111.88B | $38.18M |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Indonesia Energy Corporation (INDO) trades at $2.79, up 0.72% with bearish technical signals despite 100% analyst buy ratings. The oil and gas explorer shows severe financial distress with negative margins (-152.72% net income) and cash burn, though recent K-29 well discoveries offer operational catalysts. Revenue remains minimal at $2.01M while losses persist, creating high-risk speculation around drilling success.
Outlook hinges on production scaling from new wells, but current fundamentals don't support valuation. High execution risk and cash flow concerns warrant caution despite optimistic analyst coverage. The stock represents a binary bet on operational turnaround versus ongoing financial deterioration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
